This paper will focus on the regulatory concerns regarding current practices of clinical pathology from the perspective of the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA). The philosophy of regulation at CBER is to use sound scientific principles, common sense, flexibility, and a case-by-case (i.e., rational, science-based) approach to aid in making a risk vs benefit assessment.
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The approval process at the FDA is dependent on the nature of the product and the regulatory experience and expertise of the sponsor and the regulating agency. The role of the FDA regulatory scientist includes not only timely product review, laboratory applications, and model building but also research on technologies and principles for regulation. Government, industry, and the public are key components influencing the regulatory environment. This meeting is a testament to the importance of interaction and dialogue among scientists, in various aspects of the drug development process, to achieve a mutual understanding of how best to evaluate products for their safety. Regulations can be expected to evolve with technology. While the procedures and requirements vary among the various regulatory agencies, there is an effort to integrate and coordinate the process, both domestically and internationally.
The analysis or assessment of risk differs for each risk agent. The risks associated with environmental chemicals, foods and food additives, veterinary drugs, medical devices, biologics, and drugs require different types of judgment and therefore demand different data requirements. In general, for drugs, biologics, and medical devices, the human dose/ exposure is known. Animal studies are performed to characterize potential toxicity to determine that clinical exposure will be safe for humans. The intended use is an essential part of the analysis because it is used to determine risk vs benefit. In contrast, for environmental chemicals, foods and food additives, and veterinary drugs in food-producing animals, the purpose of animal studies is to provide data for risk assessment analysis to determine safe exposure levels. The human dose/exposure is usually not known. Human data exposure levels are largely derived from epidemiological data. The intended use may have little effect on assessment.
The design of animal studies and accompanying clinical pathology evaluations, while different for the various agencies, are consistent with each agency's regulatory mandate. For drugs and biologics, the goal of preclinical animal safety evaluation is to provide data to show that the human risk : benefit ratio is acceptable, i.e., that the product is safe to initiate clinical trials. The process then becomes an iterative one. Animal studies are designed throughout the development process to establish the full spectrum or any adverse effects and to provide meaningful comparisons with clinical findings. Having the opportunity to assess human exposure during clinical trials allows for the selection of the most relevant parameters to investigate more specifically on subsequent animal studies.
One of the most important messages today is that preclinical studies should never be performed just &dquo;to fulfill a regulatory requirement.&dquo; Rather, they should be designed to provide relevant information for the regulatory scientist to make an informed assessment of safety. As a means to achieving this end, there is a misconception among some industry sponsors that &dquo;more data are more useful.&dquo; There is also the misconception that regulatory scientists would prefer not to see anything &dquo;bad&dquo; in a study. In fact, the most useful data are obtained from well thought out studies that establish toxicity and provide a better understanding of the biochemical and physiological mechanisms of action. Knowledge gained from these studies will facilitate the development process. Information describing or interpreting changes in clinical pathology parameters is far more useful than efforts at minimizing or discounting the effects, examples of which are given in Table I .
The information to be gained from preclinical studies includes knowledge about the dose/activity relationship, knowledge about the relationship of route and scheduling to toxicity, and at least a fundamental understanding of potential risk for toxicity. Formal guidelines defining standard sets of parameters may be more important for evaluation of environmental chemicals and food additives because, as previously mentioned, detailed information about exposure cannot be strictly defined. Because of the varied nature of biological products (e.g., immune regulatory factors, blood, coagulation factors, albumin, thrombolytic enzymes, monoclonal antibodies, vaccines), CBER provides principles for preclinical safety evaluation rather than specific guidelines or protocols. The format for these provisions is the &dquo;points to consider&dquo; (PTC) documents. The PTC documents are intended to provide scientific guidance to improve quality, promote consistency, and provide information to the public. They encourage sponsors to think and consider those parameters that will best support the safety of their product. Examples include PTC in the Production and Testing of New Drugs and Biologic Products by Recombinant DNA Technology, PTC in the Safety Evaluation of Hemoglobin-based Oxygen Carriers, and PTC in Human Somatic Cell Therapy and Gene Therapy ( 1 ).
With new advances in technology, reevaluating the current technologies used in preclinical safety evaluation will become increasingly important to assure that they are still useful and appropriate. Scientists in industry and the government will have to decide which technologies are needed. If new technologies are identified, then they will need to be developed, validated, and standardized before their routine application. Some principles that can be applied in the generation of preclinical clinical pathology data are more useful than others. We are clearly more comfortable looking at composite analytes rather than a single analyte. In some cases, clinical pathology parameters have been considered as surrogate markers of activity. Identification of preclinical surrogate endpoints in preclinical studies may be useful in the correlation of pharmacological responses (pharmacodynamic endpoints) or in predicting adverse events or negative outcomes over time (toxicological endpoints). The information may also be useful when definitive endpoints have not been established, especially for new classes of products.
In clinical medicine, a variety of criteria establish or describe the level/grade of toxicity (e.g., the World Health Organization criteria for bilirubin 1.25 x normal is grade zero while 10x normal is grade 4 (2). However, in preclinical studies there is a lack of criteria for establishment of a positive response (e.g., is 3 x normal aspartate amino transferase [AST] moderate or severe?). How widely must this vary among species? Do absolute changes reflect differences in final interpretation for different species? Are abnormally low values important where high values are usually diagnostic (e.g., abnormally low alanine amino transferase [ALT]) or abnormally high values important where lower values are usually diagnostic (e.g., platelets)?
Most preclinical safety studies use normal animals, and most historical toxicology data have been generated in the rat and the dog. These data that have been developed over the years have provided baseline information for setting normal range values. The information is limited for nontraditional species (e.g., the ferret, the hamster). There is even less information regarding clinical pathology baseline data for various animal models of disease. In general, toxicologists are often uncomfortable about using disease models as predictors for safety, but in some cases the animal disease model may be the best model to assess toxicity. Nevertheless, it is likely that a core group of parameters can be established to measure gross organ activity/toxicity in normal animals. Additional profiles could be specified to target specific product classes and/or disease states.
The determination of toxicity is not a 1-time de-cision to be made during initial steps of product characterization. Decision making during product development is an iterative process. There should, therefore, be some comfort in making a decision to limit clinical pathology parameters, as one gains information both during preclinical development and during clinical trials. This may allow for a more careful description of target organ toxicity and/or activity. Clearly there is some risk to this approach, i.e., &dquo;in not doing it all.&dquo; However, each product class will have an established base of scientific data on which we can rely for designing the most appropriate studies for that product class. The most important contribution a clinical pathologist can make toward arriving at a better understanding of the toxicity of the product is to interpret the clinical pathology results. This is not to say that clinical pathologists should regurgitate the findings (e.g., increase in ALT, decrease in creatinine, increase in platelets). The clinical pathologist's s interpretation should consider all available study data.
Approaches to safety evaluation are varied. Different approaches will be applied for each risk agent.
The conventional or guideline-driven approach for defining a standard set of parameters may be appropriate for some classes of products. In biologics, because of the nature of the products, a nonstandardized, or nonconventional, approach has been used. While development of &dquo;the most appropriate approach to individual product characterization&dquo; will likely require additional time to plan the preclinical studies, it need not involve additional expense.
It is important to understand that animal studies are likely to be designed and performed concurrently with clinical trials. Additional studies are required as the scope of the clinical program changes. When possible, animal models or disease models are useful since enhanced toxicity may occur from synergistic effects resulting from disease-altered biochemistry. As we move toward defining surrogate markers in preclinical studies, they may actually be more relevant in disease models.
The process of preclinical safety evaluation should continue to evolve as new technologies are devel-TABLE 11. -areas of concern in the current practices of clinical pathology.
oped. These new technologies will result in the production of new and novel therapies, but they will also aid in the evaluation of the safety of the therapies. Clinical pathologists together with other professionals in the drug development process should continue to revisit the current practices and focus on areas, as summarized in Table II where Clinical pathologists should be encouraged to consider contributing to the scientific data base, which is the basis behind the regulatory principles, and not to rely strictly on implementation of rigid regulatory requirements. As principles are defined and more data become available, academia, industry, and regulatory scientists should continue to maintain an open dialogue to establish the what, the why, and the how, so that clinical pathology data can be used to better define product safety.
Dr. Cavagnaro. The Red Book contains the guidelines issued by the Center of Food Safety and Applied Nutrition. These are currently being reviewed internally and will be published as proposed guidelines in the Federal Register for comment. It is important that all of you who are interested provide comment. I would like to make one additional comment. There appears to be an overwhelming concern of &dquo;being left out&dquo; in the formation of guidelines. Speaking as one of the &dquo;chosen few&dquo; for drafting such documents, drafting guidelines is not considered one of the best assignments! Dr. Gross. When you comment on these things, do you need to support them with data?
Dr. Cavagnaro. Yes.
Dr. Gross. A lot of people just do not do that. Dr. Cavagnaro. That is a good point. Comments are most useful when supported by data. We actually have a saying at CBER, &dquo;In God we trust-everyone else bring data!&dquo;
